US 11,903,697 B2
System and method for mode switching
Naresh C. Bhavaraju, San Diego, CA (US); Michael A. Bloom, Carlsbad, CA (US); Leif N. Bowman, San Diego, CA (US); Alexandra Lynn Carlton, San Marcos, CA (US); Katherine Yerre Koehler, Solana Beach, CA (US); Hari Hampapuram, Carlsbad, CA (US); Lauren Hruby Jepson, San Diego, CA (US); Jonathan Hughes, Carlsbad, CA (US); Apurv Ullas Karnath, San Diego, CA (US); Anna Leigh Davis, Cardiff, CA (US); Peter C. Simpson, Cardiff, CA (US); and Stephen J. Vanslyke, Carlsbad, CA (US)
Assigned to DEXCOM, INC., San Diego, CA (US)
Filed by DexCom, Inc., San Diego, CA (US)
Filed on Dec. 18, 2015, as Appl. No. 14/975,437.
Application 14/975,437 is a continuation of application No. 14/862,079, filed on Sep. 22, 2015.
Claims priority of provisional application 62/053,733, filed on Sep. 22, 2014.
Prior Publication US 2016/0113558 A1, Apr. 28, 2016
Int. Cl. A61B 5/145 (2006.01); A61B 5/1455 (2006.01); A61B 5/1486 (2006.01); A61B 5/00 (2006.01); A61M 5/172 (2006.01); A61B 5/1495 (2006.01); G16H 40/63 (2018.01); G16H 40/40 (2018.01)
CPC A61B 5/14532 (2013.01) [A61B 5/0002 (2013.01); A61B 5/1455 (2013.01); A61B 5/1486 (2013.01); A61B 5/1495 (2013.01); A61B 5/14503 (2013.01); A61B 5/14546 (2013.01); A61B 5/7221 (2013.01); A61B 5/7275 (2013.01); A61B 5/7282 (2013.01); A61B 5/742 (2013.01); A61B 5/746 (2013.01); A61B 5/7435 (2013.01); A61B 5/7475 (2013.01); A61M 5/1723 (2013.01); G16H 40/40 (2018.01); G16H 40/63 (2018.01); A61B 5/0004 (2013.01); A61B 5/6898 (2013.01); A61B 5/72 (2013.01); A61B 2560/0223 (2013.01); A61B 2560/0487 (2013.01); A61M 2230/005 (2013.01); A61M 2230/201 (2013.01); Y02A 90/10 (2018.01)] 21 Claims
OG exemplary drawing
 
1. A computer-implemented method comprising:
receiving measurement data indicative of a glucose concentration of a user measured by a glucose sensor of an artificial pancreas system, the artificial pancreas system including the glucose sensor and an insulin delivery pump;
controlling the artificial pancreas system to operate in a therapeutic mode in which a numerical value of the glucose concentration of the user is displayed via a user interface and the insulin delivery pump is controlled to automatically administer insulin to the user based on the glucose concentration of the user measured by the glucose sensor of the artificial pancreas system, wherein the artificial pancreas system is configured to operate in a closed loop while in the therapeutic mode;
transitioning the artificial pancreas system directly from the therapeutic mode to an adjunctive mode based on a comparison of real time usability data against one or more transition criteria, wherein the real time usability data indicates a reliability or accuracy of the measurement data received from the glucose sensor, and wherein the transitioning from the therapeutic mode to the adjunctive mode occurs when the real time usability data indicates that the reliability or accuracy of the measurement data received from the glucose sensor is below a threshold; and
receiving subsequent measurement data indicative of a subsequent glucose concentration of the user measured by the glucose sensor of the artificial pancreas system; and
controlling the artificial pancreas system to operate in the adjunctive mode in which a visual indication of a zone, range, or trend associated with the subsequent glucose concentration is displayed via the user interface, wherein the subsequent measurement data received from the glucose sensor is not used to control the insulin delivery pump while the artificial pancreas system is operating in the adjunctive mode.